M 0002

Drug Profile

M 0002

Alternative Names: M0002; RWJ 351647; SPD 556

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Developer Shire-Movetis NV
  • Class 3-ring heterocyclic compounds; Amides; Small molecules
  • Mechanism of Action Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ascites

Most Recent Events

  • 22 Feb 2012 Discontinued - Phase-II for Ascites in Europe (PO)
  • 06 Jun 2007 Phase-II clinical trials in Ascites in Europe (PO)
  • 07 Jun 2005 Phase-I clinical trials in Hyponatraemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top